ATS 2018 International Conference

A Phase 2a Randomized, Double-Blind, Placebo-Controlled Trial of AZD8871, a Novel Dual-Acting Bronchodilator in COPD Patients

Location: 32A

Session Type: Late Breaking Mini Symposium

Monday

May

9:15 AM

9:30 AM

Speaker(s)/Author(s)

Ulrika Wahlby Hamren

PhD
AstraZeneca

Beatriz Seoane

MSc
AstraZeneca

Victor Balaguer

MSc, MEng
AstraZeneca

Marie-Pierre Malice

MSc
AstraZeneca

Carol Astbury

PhD
AstraZeneca

Alejhandra Lei

MD
AstraZeneca

Lali Jimenez

PhD
AstraZeneca

Ioannis Psallidas

MD, PhD
AstraZeneca

Ajay Aggarwal

MD
AstraZeneca

Dave Singh

MD, NP
Manchester Academic Health Science Centre, The University of Manchester;Medicines Evaluation Unit (MEU), University of South Manchester NHS Foundation Trust;The University of Manchester, University Ho

View Abstract

A Phase 2a Randomized, Double-Blind, Placebo-Controlled Trial of AZD8871, a Novel Dual-Acting Bronchodilator in COPD Patients

Parent Sessions

B14 - LATE BREAKING CLINICAL TRIALS AND FIRST REPORTS IN ASTHMA AND COPD...
05-21-2018 9:15 AM - 11:15 AM

Event

A Phase 2a Randomized, Double-Blind, Placebo-Controlled Trial of AZD8871, a Novel Dual-Acting Bronchodilator in COPD Patients

Speaker(s)/Author(s)

Ulrika Wahlby Hamren

Beatriz Seoane

Victor Balaguer

Marie-Pierre Malice

Carol Astbury

Alejhandra Lei

Lali Jimenez

Ioannis Psallidas

Ajay Aggarwal

Dave Singh

View Abstract

A Phase 2a Randomized, Double-Blind, Placebo-Controlled Trial of AZD8871, a Novel Dual-Acting Bronchodilator in COPD Patients

Parent Sessions